210 results
424B3
PRTG
Portage Biotech Inc
12 Apr 24
Prospectus supplement
5:22pm
, including without limitation, statements about the Company that are forward-looking in nature and, business strategy, plans and objectives
6-K
EX-99.1
PRTG
Portage Biotech Inc
12 Apr 24
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
5:21pm
of historical facts, including without limitation, statements about the Company that are forward-looking in nature and, business strategy, plans
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
, statements regarding our business strategy, plans and objectives of management for future operations and those statements preceded by, followed … partners.
Our Science Strategy
Our goal is to develop immuno-oncology therapeutics that will dramatically improve the standard-of-care for patients
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
or incorporated by reference herein, including without limitation, statements regarding our business strategy, plans and objectives of management … and our large network of experts, contract labs and academic partners.
Our Science Strategy
Our goal is to develop immuno-oncology therapeutics
424B3
PRTG
Portage Biotech Inc
4 Jan 24
Prospectus supplement
5:49pm
in nature and, business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise
6-K
EX-99.1
5wuns
4 Jan 24
Current report (foreign)
8:10am
424B3
w501e
28 Nov 23
Prospectus supplement
4:03pm
6-K
EX-99.1
0ineei11jyrdj
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
6-K
EX-99.2
vqgaykh2t7bhw
28 Nov 23
Current report (foreign)
4:01pm
424B3
32jozqe
14 Nov 23
Prospectus supplement
6:00am
6-K
EX-99.1
7e3j9gw5
13 Nov 23
Current report (foreign)
6:10am
424B3
tnh57mu1kzpgavy9der3
7 Nov 23
Prospectus supplement
4:50pm
F-1
vd4h9s ux
31 Oct 23
Registration statement (foreign)
4:05pm
424B5
ffvhghdep3 32t
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.1
umhrd6y hkyfy
29 Sep 23
Portage Biotech Announces $6.0 Million Registered Direct Offering
8:01am
6-K
EX-99.1
yho17s3vw6 yv
8 Sep 23
Current report (foreign)
4:01pm
6-K
EX-99.1
xulc8wcr 7bgtfxn
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
y2v mbarciv1wr
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
8rqtsj 63toj3vz33k
14 Aug 23
Current report (foreign)
4:52pm
6-K
EX-99.1
vjfcc m80
31 Jul 23
Current report (foreign)
6:10pm